Atria Investments Inc Raises Holdings in Solventum Corporation $SOLV

Atria Investments Inc lifted its stake in Solventum Corporation (NYSE:SOLV) by 28.3% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 14,633 shares of the company’s stock after acquiring an additional 3,232 shares during the period. Atria Investments Inc’s holdings in Solventum were worth $1,110,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently bought and sold shares of SOLV. Strengthening Families & Communities LLC increased its stake in Solventum by 376.8% during the 1st quarter. Strengthening Families & Communities LLC now owns 329 shares of the company’s stock valued at $25,000 after purchasing an additional 260 shares in the last quarter. Barrett & Company Inc. lifted its stake in shares of Solventum by 206.2% during the second quarter. Barrett & Company Inc. now owns 398 shares of the company’s stock worth $30,000 after buying an additional 268 shares during the period. IMG Wealth Management Inc. purchased a new stake in shares of Solventum during the second quarter valued at $31,000. Hara Capital LLC purchased a new stake in shares of Solventum during the first quarter valued at $38,000. Finally, Smartleaf Asset Management LLC increased its position in shares of Solventum by 193.4% in the 1st quarter. Smartleaf Asset Management LLC now owns 534 shares of the company’s stock valued at $40,000 after acquiring an additional 352 shares during the period.

Solventum Price Performance

Shares of NYSE SOLV opened at $66.25 on Friday. The company has a debt-to-equity ratio of 2.14, a current ratio of 1.22 and a quick ratio of 0.86. The stock has a market capitalization of $11.49 billion, a price-to-earnings ratio of 30.67, a PEG ratio of 2.75 and a beta of 0.48. The firm’s 50 day simple moving average is $72.00 and its 200-day simple moving average is $72.33. Solventum Corporation has a 12 month low of $60.70 and a 12 month high of $85.92.

Solventum (NYSE:SOLV) last posted its earnings results on Thursday, November 6th. The company reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.43 by $0.07. The firm had revenue of $2.10 billion during the quarter, compared to analysts’ expectations of $2.05 billion. Solventum had a net margin of 4.52% and a return on equity of 29.93%. The business’s revenue was up .7% compared to the same quarter last year. During the same period in the previous year, the business posted $1.64 EPS. Solventum has set its FY 2025 guidance at 5.980-6.080 EPS. Analysts expect that Solventum Corporation will post 6.58 EPS for the current year.

Wall Street Analysts Forecast Growth

SOLV has been the subject of a number of research reports. Piper Sandler reaffirmed an “overweight” rating and set a $94.00 price target (up previously from $87.00) on shares of Solventum in a research report on Friday, August 8th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Solventum in a report on Thursday, October 30th. Morgan Stanley upgraded Solventum from an “equal weight” rating to an “overweight” rating and upped their target price for the company from $80.00 to $103.00 in a research report on Tuesday, July 15th. Zacks Research upgraded shares of Solventum from a “hold” rating to a “strong-buy” rating in a report on Monday, September 15th. Finally, Jefferies Financial Group assumed coverage on shares of Solventum in a research note on Thursday, September 11th. They set a “hold” rating and a $80.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $84.89.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.